title: [Modulation of SIRS].
abstract: SIRS is a systemic inflammatory reaction occurring in the course of several diseases and it is considered that SIRS is hyper-cytokinemia. Recently, the control mechanism of IL-10 anti-inflammatory cytokine for the superfluous inflammatory reaction by inflammatory cytokines such as TNF has received considerable attention. IL-10 tends to inhibit monocytes/macrophages and the production of TNF, IL-1 and IL-8 is suppressed. In addition, the production of oxygen radicals and proteases from activated neutrophils is directly suppressed. IL-10 seems to control the generation of tissue injury that accompanies neutrophil activation by also suppressing CD11a, CD11b and TNF receptor expression of neutrophil surface directory. In this study, we observed the effect of a drug that controls cytokine production by lymphocytes after LPS loading, using an antibacterial agent and steroids, to observe the effect of the drug on the control mechanism of SIRS. As the result, TNF production by lymphocytes was suppressed by macrolide, new quinolone and fosphomycin. Steroid also dosage-dependently suppressed TNF production of lymphocytes after 24 hours of incubation while IL-10 production increased. From these results, it was considered that some antibacterial agents and steroids have anti-inflammatory or a modulating effect on inflammation. Clinically, the control of inflammation in patients with SIRS by these drugs is expected.
authors.affiliation: First Department of Internal Medicine, Kyorin University School of Medicine, Mitaka.
authors.forename: S
authors.initials: S
authors.lastname: Kawai
mesh_terms: D042462:4-Quinolones; D000900:Anti-Bacterial Agents / Q000494:pharmacology / Q000627:therapeutic use; D000890:Anti-Infective Agents / Q000494:pharmacology / Q000627:therapeutic use; D000893:Anti-Inflammatory Agents / Q000494:pharmacology / Q000627:therapeutic use; D006801:Humans; D007375:Interleukin-1 / Q000378:metabolism; D016753:Interleukin-10 / Q000378:metabolism / Q000502:physiology; D016209:Interleukin-8 / Q000378:metabolism; D018942:Macrolides; D008264:Macrophages / Q000378:metabolism; D018375:Neutrophil Activation / Q000187:drug effects; D013256:Steroids; D018746:Systemic Inflammatory Response Syndrome / Q000188:drug therapy / Q000378:metabolism; D013601:T-Lymphocytes / Q000378:metabolism; D014409:Tumor Necrosis Factor-alpha / Q000378:metabolism
chemical_list: D042462:4-Quinolones; D000900:Anti-Bacterial Agents; D000890:Anti-Infective Agents; D000893:Anti-Inflammatory Agents; D007375:Interleukin-1; D016209:Interleukin-8; D018942:Macrolides; D013256:Steroids; D014409:Tumor Necrosis Factor-alpha; D016753:Interleukin-10